短毛五加总皂苷在体外抑制人血小板聚集和血小板因子4释放

短毛五加总皂苷在体外抑制人血小板聚集和血小板因子４释放１陈小川，夏兰２，胡松３，黄光（海南医学院药理教研室，海口５７０１０２；２海南省人民医院血液室，海口５７００１１；３海南心血管病医院，海口５７０２０８，中国）关键词短毛五加；皂苷类；血小板聚集；血...     

水溶性槲皮素的研究

水溶性槲皮素的研究佘戟１）莫丽儿康铁邦梁念慈（广东医学院化学教研室、医用生物化学研究所，湛江５２４０２３）槲皮素（ｑｕｅｒｃｅｔｉｎ；３，３′，４′，５，７－ｐｅｎｔａｈｙｄｒｏｘｙｆｌａｖｏｎｅ）存在于许多植物体内，它的提取和纯化已有大量的报道．国...     

1，2，3，9－四氢－9－甲基－4H－咔唑－4－酮的合成

１，２，３，９－四氢－９－甲基－４Ｈ－咔唑－４－酮的合成匡永清，张生勇，孙晓莉（第四军医大学化学教研室，西安７１００３２）ＳＹＮＴＨＥＳＩＳＯＦ１，２，３，９－ＴＥＴＲＡＨＹＤＲＯ－９－ＭＥＴＨＹＬ－４－ＯＮＥ￥ＫＵＡＫＧ－ＹｏｎｇＱｉｎｇ；ＺＨＡＮ...     

卡托普利对血管平滑肌细胞内pH影响

卡托普利对血管平滑肌细胞内ｐＨ影响１齐建华，章鲁２，王军，顾培坤，金正均，黄明智３（上海第二医科大学药理教研室，２计算机医学应用教研室，３上海市高血压研究所，上海２０００２５，中国）王新明（中国科学院上海细胞生物学研究所，上海２０００３１，中国）关键...     

两种二氢吡啶衍生物的合成和降压活性

两种二氢吡啶衍生物的合成和降压活性张三奇１）（第四军医大学西京医院药剂科，西安７１００３２）招明高冯锐２）梅其炳赵德化（第四军医大学药理学教研室，西安７１００３２）关键词二氢吡啶衍生物；合成；降压活性１，４二氢３，５吡啶二羧酸酯类化合物是一类重要...     

全反式维A酸对血管平滑肌细胞增殖,细胞内钙离子和氢离子含量的影响

全反式维Ａ酸对血管平滑肌细胞增殖，细胞内钙离子和氢离子含量的影响１余晨光章鲁２顾培坤３魏丕敬３金正均３（上海第二医科大学神经生物学教研室，２计算机室，３药理学教研室，上海２０００２５）血管平滑肌细胞（ｖａｓｃｕｌａｒｓｍｏｏｔｈｍｕｓｃｌｅｃｅｌｓ，...     

钾通道药理的研究进展

钾通道药理的研究进展陈志刚王佩徐建华（浙江医科大学药学系药理学教研室，杭州３１００３１）中国图书分类号Ｒ９７１；Ｒ９７２．４；Ｒ９７４．３钾通道是一类分布很广的膜离子通道。８０年代以来，由于电压钳和单细胞通道记录等新技术的应用，对Ｋ＋通道的认识逐渐深...     

本期广告索引

封面：上海卡乐康包衣技术有限公司；封二：德固萨－赫斯太平洋有限公司上海代表处；彩插１：德国沙多利斯公司上海办事处；彩插２：上海现代国际展览有限公司；彩插３：美国古立德化学亚太区有限公司；彩插４：基伊埃技术设备（上海）有限公司，尼鲁分公司；插１：湖南郴州市郴湘贵金属有限以司；插２、３：大连依利特科学仪器有限公司；插４：上海威宇机电制造有限公司；彩插５：中美合资南通罗斯混合设备有限公司；彩插６、７：江阴市华英成套设备有限公司；彩插８、９：中国医药工业杂志编辑部、上海卡乐康包衣技术有限公司同贺；彩插１…     

间尼索地平致突变作用

间尼索地平致突变作用王丛妙，张立玮，傅绍萱，李蕴山（空军石家在医院，石家在０５００８１；河北医学院附属第四医院肿瘤研究所药理学教研室，石家在０５００１７）间尼索地平（ｉｓｏｂｕｌｙｌｍｅｔｈｙｄｒｏ－２，６－ｄｉｍｅｔｈｙｌ－４－（３－ｎｉｔｒｏｐｈ...     

本期广告索引

封面：天津大学无线电厂、天津大学精密仪器厂；封二：北京赛多利斯天平有限公司；彩插１：浙江海正药业股份有限公司；彩插２：基伊埃技术设备（上海）有限公司；彩插３：上海曼迪新科技合作公司；彩插４：哈尔滨市方达电子技术开发有限公司；插１：上海威宇机电制造有限公司；插２、插３：大连依利特科学仪器有限公司；插４：山东济宁超声电子仪器厂；彩插５：梅特勒－托利多仪器（上海）有限公司；彩插６：广西荔浦药用明胶厂；插５：江苏省久吾高科技发展有限公司，南京化工大学膜科学技术研究所；插６：西安交通大学思源精细化工公司；…     

Quantitative in vivo and in vitro sex differences in artemisinin metabolism in rat

1. The pharmacokinetics of the antimalarial compound artemisinin were compared in the male and female Sprague-Dawley rat after single dose i.v. (20 mg.kg) or i.p. (50 mg.kg) administration of an emulsion formulation. 2. Plasma clearance of artemisinin was 12.0 (95% confidence interval: 10.4, 13.0) l.h. kg in the male rat and 10.6 (95% CI: 7.5, 15.0) l.h. kg in the female rat suggesting high hepatic extraction in combination with erythrocyte uptake or clearance. Artemisinin half-life was 0.5 h after both routes of administration in both sexes. Values for plasma clearance and half-lives did not statistically differ between the sexes. 3. After i.p. administration artemisinin AUCs were 2-fold higher in the female compared with male rat (p 0.001). Artemisinin disappearance was 3.9-fold greater in microsomes from male compared with female livers and it was inhibited in male microsomes by goat or rabbit serum containing antibodies against CYP2C11 and CYP3A2 but not CYP2B1 or CYP2E1. 4. The unbound fraction of artemisinin in plasma was lower (p 0.001) in plasma obtained from the male (8.8 2.0%) compared with the female rat (11.7 2.2%). 5. The possibility of a marked sex difference, dependent on the route of administration, has to be taken into account in the design and interpretation of toxicological studies of artemisinin in this species.     

Interindividual variability in metabolic activation in humans in vivo

In assessing interindividual variability in metabolic activation, the toxic metabolite is often too unstable for conventional analysis. Possible alternatives include a stable product of the reactive metabolite e.g. cysteinyl derivatives of N-acetyl-4-benzoquinoneimine, the toxic metabolite of paracetamol, adducts with DNA or protein, and indirect measurement of the activity of the enzyme(s) producing the active metabolite. An example of the last approach is the use of furafylline, a highly specific inhibitor of human CYP1A2, to determine the extent of the metabolic activation of the cooked food mutagens PhIP and MeIQx. The extent of inhibition, determined from levels of unchanged amine in urine, is an indirect measure of the activity of the activation pathway. Further refinement of this approach, allied to improved measures of the biological process of interest should prove of value in evaluating interindividual variability and its role in the risk assessment process.     

Theophylline kinetics in peripheral tissues in vivo in humans

Several biochemical and cellular effects have been described for methylxanthines under in vitro conditions. However, it is unknown, whether threshold concentrations required to exert these effects are attained in target tissues in vivo. We therefore employed the microdialysis technique for measuring theophylline concentrations in peripheral tissues under in vivo conditions.Following in vitro and in vivo calibration, microdialysis probes were inserted into the medial vastus muscle and into the periumbilical subcutaneous adipose layer of healthy volunteers. Following single oral dose administration of 300 mg or i.v. infusion of 240 mg theophylline, in vivo time courses of theophylline concentrations were monitored in tissues and plasma. Major pharmacokinetic parameters (c_max, t_max, AUC) were calculated for plasma and tissue time courses. The mean AUC_tissue /AUC_plasma-ratio was 0.56 (p.o.) and 0.55 (i.v.) for muscle and 0.55 (p.o.) and 0.72 (i.v.) for subcutaneous adipose tissue.We conclude that microdialysis provides important information on the distribution and the tissue pharmacokinetics of theophylline.Abbreviations FPIA Fluorescence polarisation immuno assay - AUC Area under the curve - t_max Time to peak concentration - c_max Peak concentration     

Quantitative in vivo and in vitro sex differences in artemisinin metabolism in rat

1. The pharmacokinetics of the antimalarial compound artemisinin were compared in the male and female Sprague-Dawley rat after single dose i.v. (20 mg x kg(-1)) or i.p. (50 mg x kg(-1)) administration of an emulsion formulation. 2. Plasma clearance of artemisinin was 12.0 (95% confidence interval: 10.4, 13.0) 1 x h(-1) x kg(-1) in the male rat and 10.6 (95% CI: 7.5, 15.0) 1 x h(-1) x kg(-1) in the female rat suggesting high hepatic extraction in combination with erythrocyte uptake or clearance. Artemisinin half-life was approximately 0.5 h after both routes of administration in both sexes. Values for plasma clearance and half-lives did not statistically differ between the sexes. 3. After i.p. administration artemisinin AUCs were 2-fold higher in the female compared with male rat (p < 0.001). Artemisinin disappearance was 3.9-fold greater in microsomes from male compared with female livers and it was inhibited in male microsomes by goat or rabbit serum containing antibodies against CYP2C11 and CYP3A2 but not CYP2B1 or CYP2E1. 4. The unbound fraction of artemisinin in plasma was lower (p < 0.001) in plasma obtained from the male (8.8 +/- 2.0%) compared with the female rat (11.7 +/- 2.2%). 5. The possibility of a marked sex difference, dependent on the route of administration, has to be taken into account in the design and interpretation of toxicological studies of artemisinin in this species.     

休克时血中氧自由基的变化

本实验测定10名休克患者血浆和红细胞的丙二醛(MDA)、血浆总抗的氧化活性(AOA)的含量。结果表明:休克病人红细胞膜和血浆 MDA 含量(4.298±0.722;5.348±0.834)与对照组(3.235±0.682;4.356±1.081)比较明显增高(P<0.05);血浆 AOA(39.65±7.858)与对照组(48.21±10.81)比较明显降低(P<0.01)。提示:休克时,患者机体内自由基反应增强是引起组织细胞损伤的原因之一。     

Trichinellosis in immigrants in Switzerland

We describe a case of trichinellosis diagnosed at the Division of Infectious Diseases, Hospital of Lugano, in January 2009. This case was associated with a cluster of cases and was traced to the consumption of contaminated meat after a wild boar hunt in Bosnia.     

Hyperkalaemia in patients in hospital

A survey of all laboratory blood specimens with a plasma potassium concentration greater than or equal to 5.5 mmol/L was conducted over a three month period. Of 331 specimens with hyperkalaemia, 71 were excluded because the specimens was haemolysed, old or contaminated. The laboratory served a population of 348,561 and during this time measured the plasma potassium on 25,016 occasions. Sixty-six outpatients and 20 neonates were not evaluated. The survey was undertaken on 86 of 102 inpatients (46 males), 48 of whom were over 66 years of age. Fifty-seven patients were admitted under a medical service and 29 under a surgical service. Fifty-nine had a single episode of hyperkalaemia. Thirty-two underwent a surgical procedure. The commonest contributing factor was impaired renal function which was present in 71 (83%) patients. Although a definitive causative role for drugs could be identified in only five patients, in 52 (60%) patients drugs were a contributing factor (potassium supplements 24, ACE inhibitors 16, nonsteroidal antiinflammatory drugs 12). Thirty-five of the 86 (41%) patients died during their hospital admission. Nineteen of the 35 deaths occurred within three days of the hyperkalaemia being recorded. A normal plasma potassium was eventually documented in 50 of the 86 patients. Of the remaining 36 patients, 25 (69%) subsequently died. In general the treatment of patients with hyperkalaemia focused on identifying and treating the underlying cause. Hyperkalaemia must always be considered seriously and regard given to the overall clinical status of the patient, with particular attention to drug therapy, renal and cardiac function, acid base status and the possibility of sepsis.